Document Detail

Novel therapy for type 1 diabetes: Autologous hematopoietic stem cell transplantation.
MedLine Citation:
PMID:  23190701     Owner:  NLM     Status:  In-Data-Review    
Type 1 diabetes is characterized pathologically by autoimmune insulitis-related islet β-cell destruction. Although intensive insulin therapy for patients with type 1 diabetes can correct hyperglycemia, this therapy does not prevent all diabetes-related complications. Recent studies have shown that autologous hematopoietic stem cell transplantation (HSCT) is a promising new approach for the treatment of type 1 diabetes by reconstitution of immunotolerance and preservation of islet β-cell function. Herein we discuss the therapeutic efficacy and potential mechanisms underlying the action of HSCT and other perspectives in the clinical management of type 1 diabetes.
Lirong Li; Weiqiong Gu; Dalong Zhu
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of diabetes     Volume:  4     ISSN:  1753-0407     ISO Abbreviation:  J Diabetes     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101504326     Medline TA:  J Diabetes     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  332-7     Citation Subset:  IM    
Copyright Information:
© 2012 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.
Division of Endocrinology, The Affiliated Drum Tower Hospital of Nanjing University, Nanjing, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Analysis of two kinds of tree as physical barriers against erythemal UVB radiation received.
Next Document:  Positive correlation between chronic hyperglycemia and serum fetuin-A levels in middle-aged and elde...